NEW YORK, Feb. 16 Reportlinker.com announces that a new market research report is available in its catalogue:
Shire plc: PharmaVitae Profile
Advertisement
http://www.reportlinker.com/p0177526/Shire-plc-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Advertisement
Reasons to Purchase
*Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector
*Assess Shire's strategy for sustaining its market-leading ADHD portfolio beyond the genericization of blockbuster Adderall XR
*Analyze the impact of recent acquisitions (TKT, New River Pharmaceuticals, Jerini) on Shire's financial and sales performance over 2008-14
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 4
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Shire plc: PharmaVitae forecasts at a glance 8
Strategic insight 9
Shire's ADHD franchise growth 9
Corporate restructuring: growth via M&A 10
SWOT analysis 12
Strengths 12
Weaknesses 13
Opportunities 14
Threats 15
Table of Contents 15
Table of figures 17
Chapter 3 Quarterly news update 18
Product developments 18
Deals and alliances 19
Product deals 19
Technology deals 20
M&A activity 21
Company announcements 21
Future product milestones 22
Chapter 4 Company introduction 23
Key findings 23
Background 24
Key corporate developments 24
M&A history 25
Acquisition of Imperial Pharmaceutical Services 25
Acquisition of Pharmavene 26
Acquisition of Richwood 26
Merger with Roberts Pharmaceutical Corporation 26
Acquisition of Fuisz Technologies' EU subsidiaries 26
Acquisition of BioChem Pharma 26
Acquisition of Atlantic Pharmaceutical 26
Divestment of OTC products 26
Divestment of vaccines business 27
Acquisition of Transkaryotic Therapies 27
Acquisition of New River Pharmaceuticals 27
Divestment of non-core products 27
Acquisition of Jerini 27
Current corporate structure 28
Specialty Pharmaceuticals 28
Human Genetic Therapies 28
Chapter 5 Company sales 29
Key findings 29
Prescription pharmaceutical sales and growth rate analysis, 2002-14 30
Product analysis 32
Product analysis, 2002-08 33
Product analysis, 2008-14 36
Therapy area analysis 39
Geographic analysis 41
Launch/core/expiry analysis 44
Explanation of launch/core/expiry analysis 44
Launch analysis, 2008-14 45
Core analysis, 2008-14 47
Expiry analysis, 2008-14 48
Launch/core/expiry configuration, 2008-14 49
Molecule type analysis 50
Externalization analysis 53
Chapter 6 Company financials 55
Key findings 55
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 56
Operating costs and profit analysis 57
Operating costs and profit analysis, 2002-08 58
Operating cost ratio and profit margin analysis, 2002-08 59
Operating cost ratio and profit margin analysis, 2008-14 60
Operating costs and profit analysis, 2008-14 61
Chapter 7 Key products and competitors 62
Key findings 62
Overview 63
Central nervous system 64
Vyvanse 64
Overview 64
Sales forecast 65
Vyvanse-sustains Shire's ADHD focus beyond Adderall XR 65
Vyvanse tackles Adult ADHD market 66
Shire to gain growth in immature EU ADHD market with Vyvanse 66
Actavis' challenge to Vyvanse's US exclusivity represents a longer-term threat to sales 66
Intuniv 67
Overview 67
Sales forecast 68
Intuniv is Shire's newest ADHD offering 68
As a non-stimulant, Intuniv competes against Strattera 68
Datamonitor maintains the view that positioning as a second-line treatment option will limit uptake of Intuniv 69
More restrictive scheduling for Vyvanse raises forecasts for Intuniv 69
Daytrana 70
Overview 70
Sales forecast 71
Daytrana is the first transdermal patch formulation of methylphenidate 71
Withdrawal of Daytrana European Marketing Authorization Application (MAA) in March 2009 71
Voluntary market recall of a limited portion of Daytrana patches unlikely to threaten long-term sales 72
Endocrine, metabolic and genetic disorders 73
Elaprase 73
Overview 73
Sales forecast 74
Enzyme replacement therapy Elaprase was gained in TKT acquisition 74
Cost is also key to Elaprase's success 74
Patent protection extended in 2008 74
Replagal 75
Overview 75
Sales forecast 76
Replagal gains access to US market following Fabrazyme manufacturing concerns 76
Replagal becomes Shire's first HGT offering 76
Fabrazyme shortage grants US opportunity for Replagal 77
Velaglucerase alfa 78
Overview 78
Sales forecast 79
Limited availability of velaglucerase alfa until 2010 79
Velaglucerase alfa to compete with Genzyme's Cerezyme 79
Shire's clinical data was solid, but is there an unmet need? 80
Gastroenterology 81
Lialda / Mezavant 81
Overview 81
Sales forecast 82
Shire to roll-out Lialda across the rest of the EU 82
Lialda and Pentasa can co-exist in the US market 82
Takeda/TAP co-promotion from 2008 83
Pricing may prove a resistor to Lialda's sales growth 83
Pentasa 84
Overview 84
Sales forecast 85
Bullets Shire license Pentasa from Ferring for the US market 85
US patent expiry in 2008 unlikely to impact sales 85
Pentasa and Lialda co-exist without signs of cannibalization 86
Genitourinary 87
Fosrenol 87
Overview 87
Sales forecast 88
Fosrenol licensed from AnorMED 88
Abbott terminates co-promotion agreement for the US market 88
US market flattening out, EU and RoW to show strong growth 88
Generic threat lingers on... 89
Chapter 8 Appendix 90
R&D pipeline 90
References 91
Abbreviations 91
Exchange rates 92
About Datamonitor 93
About Datamonitor Healthcare 93
Datamonitor consulting 93
Disclaimer 94
Disclaimer 95
List of Tables
Table 1: Shire - PharmaVitae forecasts at a glance 8
Table 2: Shire key product developments, 2009 18
Table 3: Shire product deals and alliances, 2009 19
Table 4: Shire technology deals and alliances, 2009 20
Table 5: Shire M&A activity, 2009 21
Table 6: Shire company announcements, 2009 21
Table 7: Shire future product milestones, 2009-11 22
Table 8: Shire product portfolio overview ($m), 2002-08 33
Table 9: Shire product portfolio overview ($m), 2008-14 36
Table 10: Shire prescription pharmaceutical sales by therapy area ($m), 2008-14 40
Table 11: Shire prescription pharmaceutical sales by geographic region ($m), 2008-14 42
Table 12: Shire launch portfolio overview ($m), 2008-14 45
Table 13: Shire core portfolio overview ($m), 2008-14 47
Table 14: Shire expiry portfolio overview ($m), 2008-14 48
Table 15: Shire prescription pharmaceutical sales by molecule type ($m), 2008-14 51
Table 16: Shire prescription pharmaceutical sales by source ($m), 2008-14 54
Table 17: Total Shire sales by business unit ($m), 2002-08 56
Table 18: Shire operating revenue/cost analysis ($m), 2002-08 58
Table 19: Shire operating cost ratio analysis (% of total revenues), 2002-08 59
Table 20: Shire operating cost ratio analysis (% of total revenues), 2008-14 60
Table 21: Shire operating revenue/cost analysis ($m), 2008-14 61
Table 22: Key products overview 63
Table 23: Vyvanse: overview 64
Table 24: Vyvanse: sales forecast ($m), 2008-14 65
Table 25: Intuniv: overview 67
Table 26: Intuniv: sales forecast ($m), 2008-14 68
Table 27: Daytrana: overview 70
Table 28: Daytrana: sales forecast ($m), 2008-14 71
Table 29: Elaprase: overview 73
Table 30: Elaprase: sales forecast ($m), 2008-14 74
Table 31: Replagal: overview 75
Table 32: Replagal: sales forecast ($m), 2008-14 76
Table 33: Velaglucerase alfa: overview 78
Table 34: Velaglucerase alfa: sales forecast ($m), 2008-14 79
Table 35: Lialda / Mezavant: overview 81
Table 36: Lialda / Mezavant: sales forecast ($m), 2008-14 82
Table 37: Pentasa: overview 84
Table 38: Pentasa: sales forecast ($m), 2008-14 85
Table 39: Fosrenol: overview 87
Table 40: Fosrenol: sales forecast ($m), 2008-14 88
Table 41: Shire's R&D pipeline (Phase I-registration) 90
Table 42: Exchange rates, 2009 92
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Shire prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Shire's financial performance ($m), 2002-14 7
Figure 4: Shire ADHD franchise - switching strategy, 2001-14 9
Figure 5: Shire revenue by source of product, $m, 2002-14 10
Figure 6: Shire SWOT analysis 12
Figure 7: Shire M&A/divestment history 25
Figure 8: Current corporate structure 28
Figure 9: Shire prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 30
Figure 10: Key product sales ($m), 2002-14 32
Figure 11: Shire key sales growth drivers and resistors ($m), 2002-08 34
Figure 12: Shire key sales growth drivers and resistors ($m), 2008-14 37
Figure 13: Shire prescription pharmaceutical sales by therapy area ($m), 2002-14 39
Figure 14: Shire prescription pharmaceutical sales by geographic region ($m), 2002-14 41
Figure 15: Shire launch/core/expiry configuration ($m), 2008-14 49
Figure 16: Shire prescription pharmaceutical sales by molecule type ($m), 2002-14 50
Figure 17: Shire prescription pharmaceutical sales by source ($m), 2002-14 53
Figure 18: Shire operating revenue/cost analysis ($m), 2002-14 57
To order this report:
Pharmaceutical Industry: Shire plc: PharmaVitae Profile
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)-652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
